The FDA has approved Pfizer's BCMAxCD3 bispecific antibody Elrexfio as another off-the-shelf treatment option for people with multiple myeloma who have exhausted at least
Johnson & Johnson has secured another regulatory approval for its BCMAxCD3 bispecific antibody for multiple myeloma – Tecvayli – adding to the wide range of therapies available for the
Johnson & Johnson has its first worldwide regulatory approval – in the EU – for Tecvayli, one of two much-anticipated bispecific antibodies the drugmaker has developed for patients with
Seismic Therapeutic has raised $121 million in second-round financing that will be used to take its two lead drugs through early-stage clinical testing.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio